

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/415, 31/445, 31/47, 31/495, 31/535, C07D 231/56, 401/12, 403/00, 413/00		A1	(11) International Publication Number: WO 96/33713 (43) International Publication Date: 31 October 1996 (31.10.96)
(21) International Application Number: PCT/US96/03551 (22) International Filing Date: 14 March 1996 (14.03.96) (30) Priority Data: 08/405,119 16 March 1995 (16.03.95) US 08/485,956 7 June 1995 (07.06.95) US (60) Parent Application or Grant (63) Related by Continuation US 08/485,956 (CON) Filed on 7 June 1995 (07.06.95) (71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indi- anapolis, IN 46285 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): CATLOW, John, T. [US/US]; Apartment D, 5368 Rue Deville, Indianapolis, IN 46220 (US). COHEN, Marlene, L. [US/US]; 10532 Cop- pergate, Carmel, IN 46032 (US). MARTINELLI, Michael, J. [US/US]; 5242 Wilton Wood Court, Indianapolis, IN 46254 (US). SCHAUS, John, M. [US/US]; 135 Raintree			Drive, Zionsville, IN 46077 (US). SWANSON, Steven, P. [US/US]; 11519 Old Oakland Boulevard North, Indianapo- lis, IN 46236 (US). THOMPSON, Dennis, C. [US/US]; 1722 Friendship Drive, Indianapolis, IN 46217 (US). WIL- SON, Thomas, M. [US/US]; 1193 Greenlawn, Speedway, IN 46224 (US). (74) Agents: JONES, Joseph, A. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). (81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.
(54) Title: INDAZOLECARBOXAMIDES (57) Abstract Indazolecarboxamides are used as antagonists and partial agonists for the serotonin receptor 5-HT ₄ and provide therapeutic methods for treatment of disorders caused by or affected by dysfunction of the 5-HT ₄ receptor.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam


INDAZOLECARBOXAMIDES

The present invention belongs to the fields of pharmacology and synthetic organic chemistry, and provides a series of indazolecarboxamides which are partial agonists and antagonists of the serotonin 5-HT₄ receptor.

Processes in the brain and other organs involving serotonin as a neurotransmitter have been a major field of pharmacological research for some decades. A large number of processes which depend on serotonin have been identified, and numerous therapeutic compounds which affect such processes are in widespread use. More than a dozen receptors which are acted upon by serotonin have been identified. Some of the receptors' physiological mechanisms have been identified, and others are still the subject of extended and active research.

One of the more recently identified serotonin receptors is known as 5-HT₄. Therapeutic methods making use of the 5-HT₄ receptor have been held back by the lack of compounds which affect the 5-HT₄ receptor without substantial effect at other receptors. The present invention provides a series of new pharmaceutical agents which have high affinity and selectivity at the 5-HT₄ receptor.

The present invention provides compounds of the formula



wherein:

R is hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl;

-2-

R¹ is hydrogen, halo, C₁-C₄ alkyl, hydroxy, C₁-C₄ alkoxy or alkylthio, cyano, trifluoromethyl, carboxamido, mono- or di(C₁-C₄ alkyl)carboxamido;

m, n and o are independently 0-5, provided that the sum of m, n and o is 2-5;

R² is hydrogen or C₁-C₄ alkyl;

R³ and R⁴ combine with the nitrogen atom to which they are attached to form 1-pyrrolidinyl, 1-piperazinyl, 1,2,3,4-tetrahydro-2-isoquinolinyl, 2,3-dihydro-1-indolinyl, 4-morpholinyl, 1-piperidinyl or 1-hexamethyleneiminyl, substituted with

phenyl, naphthyl, (phenyl or naphthyl)(C₁-C₃ alkyl), (phenyl or naphthyl)(C₁-C₃ alkanoyl), amino, mono- or di(C₁-C₄ alkyl)amino, or a group of the formula -NH-Y-R⁵; provided that a piperazinyl or morpholinyl group may not be substituted with amino, mono- or di(C₁-C₄ alkyl)amino, or -NH-Y-R⁵;

wherein a phenyl or naphthyl group is unsubstituted or substituted with 1-3 halo, C₁-C₃ alkyl or C₁-C alkoxy groups;

Y is carbonyl, sulfonyl, aminocarbonyl or oxycarbonyl;

R⁵ is C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₆-C₁₁ bicyclo- or tricycloalkyl, (phenyl or naphthyl)(C₁-C₃ alkyl), phenyl or naphthyl;

wherein a cycloalkyl, bicyclo- or tricycloalkyl, phenyl or naphthyl group is unsubstituted or substituted with 1-3 hydroxy, halo, C₁-C₃ alkyl or C₁-C₃ alkoxy groups;

or a pharmaceutically acceptable salt thereof.

The invention further provides pharmaceutical compositions comprising the above compounds and a pharmaceutically acceptable carrier, and provides pharmaceutical methods comprising the use of the compounds of

-3-


Formula I, as well as of further compounds wherein the heterocyclic group formed by the combination of R³ and R⁴ with the nitrogen atom to which they are attached is unsubstituted.

5 The pharmaceutical methods of the present invention include a method of affecting the 5-HT₄ receptor, and in particular of providing partial agonist and antagonist activity at that receptor. Accordingly, the invention provides methods for the treatment or prophylaxis of
10 disorders caused by or affected by dysfunction of the 5-HT₄ receptor, as well as the use of the compounds of Formula I for the purposes just stated. Such disorders for which the present compounds provide treatment or prophylaxis include pathologies of the central nervous system such as anxiety,
15 pain, depression, schizophrenia, memory disorders, and dementia; pathologies of the gastrointestinal tract such as irritable bowel syndrome, nausea, gastroesophageal reflux disease, dyspepsia, gastrointestinal motility disorders, and constipation; cardiovascular disorders such as atrial
20 fibrillation, arrhythmias and tachycardia; and genitourinary disorders such as urinary retention, urinary incontinence, and pain on urination.

 The invention further provides a method of preparing those compounds of formula I wherein
25 R³ and R⁴ combine with the nitrogen atom to which they are attached to form 1-pyrrolidinyl, 1,2,3,4-tetrahydro-2-isoquinolinyl, 2,3-dihydro-1-indolinyl, 1-piperidinyl or 1-hexamethyleneiminyl, substituted with a group of the formula -NH-Y-R⁵;
30 Y is carbonyl;
R⁵ is C₃-C₈ cycloalkyl, C₆-C₁₁ bicyclo- or tricycloalkyl, (phenyl or naphthyl)(C₁-C₃ alkyl), phenyl or naphthyl;
 wherein a cycloalkyl, bicyclo- or tricycloalkyl, phenyl or naphthyl group
35 is substituted with 1-3 hydroxy groups;
or a pharmaceutically acceptable salt thereof;

-4-

comprising reacting a compound of formula I wherein R³ and R⁴ combine with the nitrogen atom to which they are attached to form amino-substituted 1-pyrrolidinyl, 1,2,3,4-tetrahydro-2-isoquinolinyl, 2,3-dihydro-1-indolinyl, 1-piperidinyl or 1-hexamethyleneiminyl, with a compound of the formula



in the presence of a coupling agent for amide-forming reactions.

In the present document, all expressions of concentration, percent, ratio and the like will be expressed in weight units unless otherwise stated, except for mixtures of solvents which will be expressed in volume units. All temperatures not otherwise stated will be expressed in degrees Celsius.

Compounds

In the above general formula, the general chemical terms have their usual meanings. For example, the terms C₁-C₆ alkyl, C₁-C₄ alkyl and C₁-C₃ alkyl include groups such as methyl, ethyl, propyl, isobutyl, isopropyl, butyl, 2-ethylbutyl, hexyl, isohexyl and the like. The terms C₃-C₆ cycloalkyl and C₃-C₈ cycloalkyl include groups such as cyclopropyl, cyclopentyl, cyclohexyl and cyclooctyl. The C₁-C₄ alkoxy, C₁-C₄ alkylthio and C₁-C₃ alkoxy groups include the corresponding alkyl groups linked through an oxygen atom or sulfur atom. The term C₁-C₃ alkanoyl includes carbonyl, acetyl and propionyl.

The term C₆-C₁₁ bicyclo- or tricycloalkyl includes groups such as bicyclo[2.2.0]hexyl, bicyclo[2.1.1]hexyl, bicyclo[3.2.0]heptyl, spiro[3.4]octyl, bicyclo[3.1.1]heptyl, bicyclo[4.2.0]octyl, spiro[3.5]nonyl, bicyclo[5.2.0]nonyl, bicyclo[7.2.0]undecyl, bicyclo[3.3.0]octyl, norbornyl, spiro[4.4]nonyl, bicyclo[4.3.0]nonyl, bicyclo[3.2.1]octyl, spiro[4.5]decyl, bicyclo[0.3.5]decyl, spiro[4.6]undecyl,

-5-


adamantyl, tricyclo[1.3.3.0]nonyl, tricyclo[1.3.3.0]nonyl, tricyclo[3.3.0.0]octyl, and spiro[cyclopentyl-1,7']norbornyl.

The term halo includes chloro, fluoro, bromo and iodo.

5 The six-membered ring of the indazole group may be substituted at any of the four available positions with one of the R^1 groups, such as fluoro, ethyl, hydroxy, propoxy, methylthio, cyano, trifluoromethyl, carboxamido, N-ethylcarboxamido or N,N-dipropylcarboxamido.

10 The 1-position nitrogen atom of the indazole may be substituted with an R group, such as methyl, propyl or cyclopentyl.

The alkylene linking group $(CH_2)_m-(CH)_n-(CH_2)_o$ may be substituted with an alkyl R^2 group, such as methyl or isopropyl. It will be seen that the linking group comprises from 2 to 5 methylene groups, and that any of the methylene groups may be absent. Thus, the linking group may be substituted on each methylene, or may be unsubstituted, or may have an alkyl R^2 substituent at any position in the group. Thus, suitable linking groups include ethylene, propylene, pentylene, and the following groups:



25 In the concept both of the novel compounds of the invention and the compounds for use in the treatment methods of the present invention, the groups R^3 and R^4 combine with the nitrogen atom to which they are attached to form a

-6-

heterocyclic group. In the concept of the novel compounds of the present invention, the heterocyclic group thus formed is substituted, and in the concept of the compounds used in the present methods, the heterocyclic group may be unsubstituted or substituted.

Cyclic groups which are substituents on the heterocyclic group, or which are components of a substituent on the heterocyclic group, may be unsubstituted or substituted with one or more groups such as chloro, hydroxy, bromo, methyl, methoxy, ethyl, propoxy or isopropyl.

Since the heterocyclic groups formed by R³ and R⁴ can be somewhat complex in their substitution, a number of typical such groups will be illustrated below to assure full comprehension by the reader.

3-phenyl-1-piperidinyl

3-(4-chloro-6-ethyl-2-naphthyl)-1-piperazinyl

5-[2-(3-methylphenyl)ethyl]-1,2,3,4-tetrahydro-2-isoquinolinyl

5-(2,4,6-trichlorophenyl)acetyl-2,3-dihydro-1-indolinyl

3-(2-norbornylcarbonylamino)-1-pyrrolidinyl

3-(cyclooctylsulfonylamino)-1-piperidinyl

3-(hexylaminocarbonylamino)-1-hexamethyleneiminyl

4-[2-(4-chloro-3,5-dimethylphenyl)ethyl]-oxycarbonylamino-1-piperidinyl

2-(4-bromo-3-ethoxy-1-naphthyl)carbonylamino-1-pyrrolidinyl

4-(6-fluoro-8-propyl-2-naphthyl)methylsulfonylamino-1-indolinyl

3-(1-adamantyl)oxycarbonylamino-1-pyrrolidinyl

6-(4-ethyl-2,6-difluorophenyl)aminocarbonylamino-2,3-dihydro-1-indolinyl

3-(3-phenylpropyl)carbonylamino-1-piperidinyl

3-(4-hydroxy-2-norbornylcarbonylamino)-1-pyrrolidinyl

3-(3-hydroxycycloheptylsulfonylamino)-1-piperidinyl

-7-

2-(4-hydroxy-2-fluoro-1-naphthyl)carbonylamino-1-pyrrolidinyl

As described in formula I, the invention includes pharmaceutically acceptable salts of the compounds defined by the above formula. Compounds of this invention react with any of a number of nontoxic inorganic and organic acids to form a pharmaceutically acceptable salt. Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like. Examples of such pharmaceutically acceptable salts thus are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, gamma-hydroxybutyrate, glycollate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, and the like. Preferred pharmaceutically acceptable acid addition salts are those formed with mineral acids such as hydrochloric acid and hydrobromic acid, and those formed with organic acids such as maleic acid and methanesulfonic acid.

All of the compounds described in the present document are active and useful, but certain groups of the compounds are particularly interesting and are preferred. The following listing sets out several groups of preferred compounds. It will be understood that each of the listings

-8-

may be combined with other listings to create additional, broader or more limited, groups of preferred compounds.

- a) R is hydrogen.
- b) R is C₁-C₃ alkyl or C₅-C₆ cycloalkyl.
- 5 c) R is hydrogen or C₁-C₃ alkyl.
- d) R is hydrogen or secondary C₁-C₆ alkyl.
- e) R¹ is hydrogen.
- f) R¹ is hydrogen, halo, alkyl or alkoxy.
- g) R² is hydrogen or methyl.
- 10 h) R² is hydrogen.
- i) The sum of m, n and o is 2-4.
- j) R³ and R⁴ combine with the nitrogen atom to which they are attached to form 1-pyrrolidinyl, 1-piperazinyl or 1-piperidinyl.
- 15 k) The substituent on the heterocyclic group formed by R³, R⁴ and the nitrogen atom is phenyl, naphthyl or (phenyl or naphthyl)(C₁-C₃ alkyl).
- l) The substituent on the heterocyclic group formed by R³, R⁴ and the nitrogen atom is amino, or mono- or di(C₁-C₄ alkyl)amino.
- 20 m) The substituent on the heterocyclic group formed by R³, R⁴ and the nitrogen atom is -NH-Y-R⁵.
- 25 n) Y is carbonyl or sulfonyl.
- o) Y is aminocarbonyl or oxycarbonyl.
- p) R⁵ is alkyl or cycloalkyl.
- q) R⁵ is adamantyl or norbornyl.
- r) R⁵ is phenyl, naphthyl or (phenyl or naphthyl)(C₁-C₃ alkyl).
- 30 s) R⁵ is substituted with 1-3 hydroxy groups.
- t) R⁵ is adamantyl substituted with 1-3 hydroxy groups.
- u) R⁵ is cycloalkyl substituted with 1-3 hydroxy groups.
- 35 v) The compound is a pharmaceutically acceptable salt.

-9-

Synthesis

The compounds of the present invention are prepared from 1H-indazole-3-carboxylic acid, bearing the desired R¹ substituent, which are well-known compounds. The basic reaction in the synthesis is the formation of a carboxamide between the indazolecarboxylic acid and an amine compound made up of the linking group and the -N(R³)(R⁴) system. Formation of the amide is readily performed in a conventional manner, as with 1,1'-carbonyldiimidazole as an activating agent in any inert solvent at a moderate temperature. Tetrahydrofuran is usually a convenient and preferred solvent, in a process carried out at a temperature of about 0° to about 50°, usually preferably at ambient temperature.

Synthesis of the amine reactant is conventional, since the reactant is made up of conventionally used and readily reactive units. It will be understood that reactants having free amino groups, hydroxy groups and the like will need to be protected in the conventional manner during the reaction, and the protecting groups removed before isolation of the product.

Further, substituent groups on the heterocyclic combined R³ and R⁴ group frequently may conveniently be added as a second step, as by the reaction of such a heterocyclic group with, for example, an aroyl halide to provide a benzoyl or naphthylcarbonyl substituent, for example. Similarly, substituted sulfonyl halides may be used as the reactant to provide substituted sulfonamido substituents where Y is sulfonyl.

It is usually preferable to add the R substituent in a second step, after the rest of the molecule has been synthesized. Reaction with an iodine-substituted derivative of the desired R substituent, in the presence of a very strong base such as sodium hydride, readily provides the desired product. The reaction is best carried out at a cool temperature in the range from about 0° to about the ambient

-10-

temperature; dimethylformamide is frequently a preferred solvent.

The particularly preferred process of this invention, illustrated in Examples 37 and 38 below, provides compounds of formula I having hydroxy-substituted R⁵ groups in an unexpectedly simple manner. An artisan would expect that the hydroxy group of the starting compound must be protected to prevent the formation of undesired polymeric substances. The examples below demonstrate, however, that reaction with the unprotected hydroxy compounds proceeds smoothly in excellent yield and purity. The process may be carried out at temperatures from about 0° C to 80° C, preferably ambient temperature to about 60° C, in protic solvents such as halogenated alkanes such as methylene chloride, chloroform and ethylene dichloride, amides such as dimethylformamide and dimethylacetamide, and ethers such as diethyl ether and tetrahydrofuran. No special protection from moisture or oxygen is necessary. The preferred coupling agent is carbonyldiimidazole, but any coupling agent such as are commonly used to assist in forming amide bonds, especially in peptide chemistry is useful. See, e.g., The Peptides, Gross and Meienhofer, Eds., Academic Press (1979), Ch. 2, for such coupling agents.

Further information about the synthesis of the present compounds may be obtained from the following preparative examples. The skilled reader will understand that the examples are illustrative but not exhaustive, and numerous useful variations of the process will occur to the reader.

Example 1

Preparation of N-[2-(1-piperidinyl)ethyl]-1H-indazole-3-carboxamide hydrochloride

To a solution of 1H-indazole-3-carboxylic acid (0.778 g, 4.8 mmol) in 25 mL tetrahydrofuran, was added 1,1'-carbonyl-diimidazole (0.778 g, 4.8 mmol). This solution was

-11-

stirred at room temperature for 3 h. To it was added dropwise a solution of 1-(2-aminoethyl)piperidine (0.615 g, 4.8 mmol) dissolved in 3.0 mL tetrahydrofuran. This solution was then stirred at room temperature for 18 h, and was
5 evaporated and diluted with water. Extraction with ethyl acetate followed by water and brine washes gave 1.14 g of low melting solid. Crystallization as the hydrochloride salt from ethyl acetate/methanol provided 0.407 g of colorless
10 crystals. Mp 252°C. Mass spectrum, $m^+ = 273$. Anal ($C_{15}H_{21}ClN_4O$) theory C, 58.34; H, 6.85; N, 18.14; found C, 58.57; H, 6.97; N, 18.02.

Example 2

Preparation of N-[2-(1-piperidinyl)ethyl]-1-(2-propyl)-
15 1H-indazole-3-carboxamide hydrochloride

A portion of the free base of Example 1 (1.41 g, 5.17 mmol) was stirred in 35 mL dimethylformamide at room temperature while sodium hydride (0.207 g, 5.17 mmol, as a
20 60% mineral oil dispersion) was added. After stirring at room temperature for 4 h, the reaction mixture was cooled in an ice bath to 15°C and 2-iodopropane (0.57 mL, 5.7 mmol) was added dropwise. The resulting mixture was stirred at room temperature for 18 h, and the solvent was evaporated and the
25 residue was dissolved in ethyl acetate. After washing the ethyl acetate solution with a 10% sodium carbonate solution, water and brine, evaporation afforded 1.76 g of oil. Flash chromatography [silica gel, methylene chloride/methanol (85/15)] yielded 1.35 g oil. Crystallization as the
30 hydrochloride salt from ethyl acetate/methanol provided 1.109 g of colorless crystals. Mp >250°C. Mass spectrum, $m^+ = 314$. Anal ($C_{18}H_{27}ClN_4O$) theory C, 61.61; H, 7.76; N, 15.97; found C, 61.85; H, 7.79; N, 15.98.

-12-

Example 3Preparation of N-[3-(1-piperidinyl)propyl]-
1H-indazole-3-carboxamide

5 Same procedure followed as described in Example 1.
The following amounts were used: 1H-indazole-3-carboxylic
acid (0.65 g, 4 mmol), 1,1'-carbonyldiimidazole (0.65 g, 4
mmol) and 1-(3-aminopropyl)piperidine (0.57 g, 4 mmol). The
ethyl acetate extracts were evaporated to 0.906 g oil. Flash
10 chromatography [silica gel, methylene chloride/methanol/
ammonium hydroxide (100/10/0.5)] yielded 0.457 g oil. Mass
spectrum, $m^+ = 287$.

Example 415 Preparation of N-[3-(1-piperidinyl)propyl]-1-(2-propyl)-
1H-indazole-3-carboxamide hydrochloride

Same procedure followed as described in Example 2.
The following amounts were used: Product from Example 3
20 (0.457 g, 1.6 mmol), sodium hydride (0.064 g, 1.6 mmol, as a
60% mineral oil dispersion) and 2-iodopropanol (0.18 mL, 1.76
mmol). Flash chromatography [silica gel, methylene
chloride/methanol/ ammonium hydroxide (100/2.5/0.5)] yielded
0.366 g oil. Crystallization as the hydrochloride salt from
25 ethyl acetate/methanol provided 0.145 g of colorless
crystals. Mp 156-158°C. Mass spectrum, $m^+ = 329$. Anal
(C₁₉H₂₉ClN₄O) theory C, 62.54; H, 8.01; N, 15.35; found C,
62.69; H, 7.91; N, 15.60.

Example 530 Preparation of N-[4-(1-piperidinyl)butyl]-
1H-indazole-3-carboxamide

To a solution of 1H-indazole-3-carboxylic acid
35 (0.745 g, 4.6 mmol) in 20 mL dimethylformamide, was added
1,1'-carbonyldiimidazole (0.745 g, 4.6 mmol). This mixture
was stirred at room temperature for 4 h, and to it was added

-13-

dropwise a solution of 1-(4-aminobutyl)piperidine (0.718 g, 4.6 mmol) dissolved in 3 mL dimethylformamide. This solution was then stirred at room temperature for 18 h, the volatiles were evaporated and the residue was diluted with water.

- 5 Extraction with ethyl acetate followed by water and brine washes gave 1.40 g of an oil which was sufficiently pure for use in the next reaction. Mass spectrum, $m^+ = 301$.

Example 6

- 10 Preparation of N-[4-(1-piperidinyl)butyl]-1-(2-propyl)-1H-indazole-3-carboxamide oxalate

- Same procedure followed as described in Example 2. The following amounts were used: Product from Example 5 (1.40 g, 4.66 mmol), sodium hydride (0.190 g, 4.66 mmol, as a 60% mineral oil dispersion) and 2-iodopropane (0.52 mL, 5.13 mmol). The ethyl acetate extracts yielded 1.48 g oil. Two crystallizations as the oxalate salt from 2-propanol provided 0.41 g of colorless crystals. Mp 143°C. Mass spectrum, $m^+ = 343$. Anal (C₂₂H₃₂N₄O₅) theory C, 61.09; H, 7.46; N, 12.95; found C, 61.05; H, 7.51; N, 13.02.

Preparation 1

- 25 Preparation of 1-(2-aminoethyl)-4-benzyloxycarbonylaminopiperidine

- To a cold (10°C) stirred mixture of 4-amino-1-benzyl-piperidine (15.2 g, 80 mmol), sodium bicarbonate (9.54 g, 110 mmol), 310 mL tetrahydrofuran and 155 mL water, was added dropwise benzyl chloroformate (14.0 mL, 98 mmol). The resulting mixture was stirred at 5-10°C for 2 h. The reaction mixture was poured onto 1000 mL water. Extraction with ethyl acetate, washing with brine, drying and evaporation of the ethyl acetate gave a viscous oil. Trituration with hexanes provided 18.56 g of solid. Mp 74-76°C. Mass spectrum, $m^+ = 324$.

-14-

The intermediate-above (18.5 g, 57 mmol) was stirred in 300 mL of 1,2-dichloroethane and cooled in an ice bath to 5°C, while 1-chloroethyl chloroformate (12.3 mL, 114 mmol) was added dropwise. After stirring at room temperature for 1 h, the 1,2-dichloroethane was evaporated to a residue. 300 mL of methanol was added to the residue and the solution heated at reflux temperature for 1 h. Evaporation of the methanol, addition of 300 mL ethyl acetate and filtration provided 15.67 g of yellow solid. Mp 178°C. Mass spectrum, $m^+ = 235$.

The intermediate above (2.07 g, 7.6 mmol), N-(2-bromoethyl)phthalimide (1.94 g, 7.6 mmol) and sodium carbonate (2.83 g, 26.6 mmol) were heated together in 40 mL dimethylformamide at 100°C for 18 h. Evaporation of the dimethylformamide, dilution with water and extraction with ethyl acetate followed by water washing, brine washing and drying provided, after evaporation, 3.15 g of solid. Crystallization from ethanol provided 1.58 g colorless crystals. Mp 159-161°C. Mass spectrum, $m^+ = 407$. Anal (C₂₃H₂₅N₃O₄) theory C, 57.80; H, 6.18; N, 10.31; found C, 57.71; H, 6.32; N, 10.20.

The intermediate prepared as above (11.9 g, 29.2 mmol) was stirred in 600 mL ethanol while 15.8 mL of hydrazine hydrate was added. This mixture was heated at reflux temperature for 4 h. After cooling, the precipitate was filtered and the filtrate was evaporated to a residue. To this residue was carefully added 250 mL of 1N sodium hydroxide solution, followed by addition of solid sodium chloride until the solution was saturated. Repeated extraction with diethyl ether, drying and evaporation gave 8.19 g of oil. Mass spectrum, $m^+ = 278$.

-15-

Example 7

Preparation of N-[2-(4-benzyloxycarbonylamino-1-piperidinyl)ethyl]-1H-indazole-3-carboxamide

5 Same procedure followed as described in Example 5.
The following amounts were used: 1H-indazole-3-carboxylic
acid (4.70 g, 29 mmol), 1,1'-carbonyldiimidazole (4.70 g,
29 mmol) and the intermediate from Preparation 1 (8.10 g,
29 mmol). The ethyl acetate extracts were evaporated to give
10 11.17 g of a solid which was sufficiently pure for use in the
next reaction. Mp 184-187°C. Mass spectrum, m^+ = 422.

Example 8

15 Preparation of N-[2-(4-benzyloxycarbonylamino-1-
piperidinyl)ethyl]-1-(2-propyl)-1H-indazole-3-
carboxamide oxalate

 Same procedure followed as described in Example 2.
The following amounts were used: Product from Example 7
20 (11.1 g, 26.3 mmol), sodium hydride (1.05g, 26.3 mmol, as a
60% mineral oil dispersion) and 2-iodopropane (2.90 mL,
29 mmol). Flash chromatography [silica gel, methylene
chloride/methanol (95/5)] yielded 10.60 g oil.
Crystallization as the oxalate salt from ethyl
25 acetate/methanol provided colorless crystals. Mp 149-151°C.
Mass spectrum, m^+ = 463. Anal (C₂₈H₃₅N₅O₇) theory C, 60.75;
H, 6.37; N, 12.65; found C, 60.53; H, 6.37; N, 12.47.

Example 9

30 Preparation of N-[2-(1-pyrrolidinyl)ethyl]-
1H-indazole-3-carboxamide

 Same procedure followed as described in Example 1.
The following amounts were used: 1H-indazole-3-carboxylic
35 acid (0.65 g, 4 mmol), 1,1'-carbonyldiimidazole (0.65 g,
4 mmol) and 1-(2-aminoethyl)pyrrolidine (0.458 g, 4 mmol).
The ethyl acetate extracts were evaporated to 0.754 g oil.

-16-

Flash chromatography [silica gel, methylene chloride/methanol/ammonium hydroxide (100/10/0.5)] yielded 0.421 g oil. Mass spectrum, $m^+ = 258$.

5

Example 10

Preparation of N-[2-(1-pyrrolidinyl)ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide hydrochloride

Same procedure followed as described in Example 2. The following amounts were used: Product from Example 9 (0.421 g, 1.63 mmol), sodium hydride (0.065 g, 1.63 mmol, as a 60% mineral oil dispersion) and 2-iodopropane (0.18 mL, 1.77 mmol). The ethyl acetate extracts were evaporated to 0.526 g oil. Flash chromatography [silica gel, methylene chloride/methanol/ammonium hydroxide (100/5/0.5)] yielded 0.385 g oil. Crystallization as the hydrochloride salt from ethyl acetate/methanol provided 0.197 g colorless crystals. Mp 210-212°C. Mass spectrum, $m^+ = 300$. Anal (C₁₇H₂₅ClN₄O) theory C, 60.61; H, 7.48; N, 16.63; found C, 60.44; H, 7.21; N, 16.58.

20

Preparation 2

Preparation of N-(2-aminoethyl)hexamethyleneimine

Hexamethyleneimine (5.7 mL, 50 mmol), N-(2-bromoethyl)phthalimide (12.7 g, 50 mmol) and sodium carbonate (13.3 g, 125 mmol) were heated together in 250 mL dimethylformamide at 100°C for 18 h. Evaporation of the dimethylformamide, dilution with water and extraction with ethyl acetate followed by water washing, brine washing and drying provided, after evaporation, 12.71 g oil. Crystallization as the tosylate salt from 2-propanol provided 13.29 g colorless crystals. Mp 180-182°C. Mass spectrum, $m^+ = 272$. Anal (C₂₃H₂₈N₂O₅S) theory C, 62.14; H, 6.35; N, 6.30; found C, 62.37; H, 6.19; N, 6.35.

25

30

35

The intermediate above (as the free base) (3.33 g, 12.2 mmol) was stirred in 220 mL ethanol while 5.0 mL of

-17-

hydrazine hydrate was added. This mixture was heated at reflux temperature for 4 h. After cooling, the mixture was filtered and the filtrate was evaporated to a residue. This residue was carefully diluted with a 1N sodium hydroxide solution, followed by extraction with diethyl ether, drying and evaporation to give 1.33 g of oil. This material was suitable for use in the next reaction.

Example 11

Preparation of N-[2-(1-hexamethyleneiminyl)ethyl]-1H-indazole-3-carboxamide

Same procedure followed as described in Example 5. The following amounts were used: Intermediate from Preparation 2 (1.33 g, 9.3 mmol), 1H-indazole-3-carboxylic acid (1.51 g, 9.3 mmol) and 1,1'-carbonyldiimidazole (1.51 g, 9.3 mmol). The ethyl acetate extracts were evaporated to a solid. Addition of cyclohexane and filtration provided 2.46 g of solid. Mp 104-115°C. Mass spectrum, $m^+ = 287$.

Example 12

Preparation of N-[2-(1-hexamethyleneiminyl)ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide hydrochloride

Same procedure followed as described in Example 2. The following amounts were used: Product from Example 11 (2.45 g, 8.55 mmol), sodium hydride (0.342 g, 8.55 mmol, as a 60% mineral oil dispersion) and 2-iodopropane (0.94 mL, 9.4 mmol). The ethyl acetate extracts were evaporated to 3.0 g oil. Flash chromatography [silica gel, methylene chloride/methanol (85/15)] yielded 1.39 g oil. Crystallization as the hydrochloride salt from ethyl acetate/methanol provided 1.05 g colorless crystals. Mp 216-218°C. Mass spectrum, $m^+ = 328$. Anal (C₁₉H₂₉ClN₄O) theory C, 62.54; H, 8.01; N, 15.35; found C, 62.52; H, 8.09; N, 15.48.

-18-

Example 13Preparation of N-[2-(4-morpholinyl)ethyl]-
1H-indazole-3-carboxamide

5 Same procedure followed as described in Example 1.
The following amounts were used: 1H-indazole-3-carboxylic
acid (0.65 g, 4 mmol), 1,1'-carbonyldiimidazole (0.65 g, 4
mmol) and 4-(2-aminoethyl)morpholine (0.52 mL, 4 mmol). The
ethyl acetate extracts were evaporated to 0.468 g solid.
10 Crystallization from ethyl acetate provided 0.267 g colorless
crystals. Mass spectrum, $m^+ = 274$.

Example 14Preparation of N-[2-(4-morpholinyl)ethyl]-1-(2-propyl)-
15 1H-indazole-3-carboxamide hydrochloride

 Same procedure followed as described in Example 2.
The following amounts were used: Product from Example 13
(0.267 g, 0.97 mmol), sodium hydride (0.040 g, 0.97 mmol, as
20 a 60% mineral oil dispersion) and 2-iodopropane (0.107 mL,
1.07 mmol). The ethyl acetate extracts were evaporated to
0.324 g oil. Two crystallizations as the hydrochloride salt
from ethyl acetate/methanol provided 0.122 g colorless
crystals. Mp 201-203°C. Mass spectrum, $m^+ = 316$. Anal
25 (C₁₇H₂₅ClN₄O₂) theory C, 57.87; H, 7.14; N, 15.88; found C,
57.71; H, 7.04; N, 16.07.

Preparation 3

Preparation of 1-(2-aminoethyl)-4-benzylpiperazine

30 1-Benzylpiperazine (8.81 g, 50 mmol), N-(2-
bromoethyl)phthalimide (12.7 g, 50 mmol) and sodium carbonate
(13.25 g, 125 mmol) were heated together in 250 mL
dimethylformamide at 100°C for 18 h. Evaporation of the
35 dimethylformamide, dilution with water and extraction with
ethyl acetate followed by water washing, brine washing and
drying, provided, after evaporation, 18.47 g oil.

-19-

Crystallization as the dihydrochloride salt from methanol provided 8.70 g colorless crystals. Mp >250°C. Mass spectrum, $m^+ = 349$. Anal ($C_{21}H_{25}Cl_2N_3O_2$) theory C, 59.72; H, 5.97; N, 9.95; found C, 60.04; H, 6.00; N, 10.04.

5 The intermediate above (8.48 g, 20 mmol) was stirred in 400 mL ethanol while 10.0 mL of hydrazine hydrate was added. This mixture was heated at reflux temperature for 4 h. After cooling, the mixture was filtered and the filtrate was evaporated to a residue. This residue was
10 carefully diluted with 300 mL 1N sodium hydroxide solution, followed by extraction with diethyl ether, drying and evaporation to give 3.69 g of oil. Mass spectrum, $m^+ = 219$.

Example 15

15 Preparation of N-[2-(4-benzyl-1-piperazinyl)ethyl]-1H-indazole-3-carboxamide

 Same procedure followed as described in Example 5. The following amounts were used: 1H-indazole-3-carboxylic
20 acid (2.72 g, 16.7 mmol), 1,1'-carbonyldiimidazole (2.72 g, 16.7 mmol) and the intermediate from Preparation 3 (3.68 g, 16.7 mmol). The ethyl acetate extracts were evaporated to 5.72 g solid. Mass spectrum, $m^+ = 364$.

25 Example 16

 Preparation of N-[2-(4-benzyl-1-piperazinyl)ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide dihydrochloride

 Same procedure followed as described in Example 2. The following amounts were used: Product from Example 15
30 (5.72 g, 15.7 mmol), sodium hydride (0.630 g, 15.7 mmol, as a 60% mineral oil dispersion) and 2-iodopropane (1.73 mL, 17.3 mmol). The ethyl acetate extracts were evaporated to 7.24 g oil. Flash chromatography [silica gel, methylene
35 chloride/methanol (93/7)] yielded 2.85 g oil. Crystallization as the dihydrochloride salt from 2-propanol provided colorless crystals. Mp 242°C. Mass spectrum, $m^+ =$

-20-

405. Anal ($C_{24}H_{33}Cl_2N_5O$)—theory C, 60.25; H, 6.95; N, 14.64; found C, 60.04; H, 7.01; N, 14.53.

Example 17

5 Preparation of N-[2-(1-piperazinyl)ethyl]-1-(2-propyl)-
1H-indazole-3-carboxamide

10 The product from Example 16, as the free base (2.35 g, 5.8 mmol), was reacted with hydrogen gas in the presence of 5% Pd/C (40°C/18h/60 PSI) in an ethanol solution. After filtering the catalyst, the ethanol was evaporated to 1.49 g oil. Flash chromatography [silica gel, methylene chloride/methanol/ammonium hydroxide (100/15/0.5)] yielded 0.951 g oil. Mass spectrum, $m^+ = 315$.

15

Example 18

Preparation of N-[2-(4-benzoyl-1-piperazinyl)ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide oxalate

20 The product from Example 17 (0.315 g, 1 mmol) and triethylamine (0.146 mL, 1.05 mmol) were stirred in 10.0 mL tetrahydrofuran and cooled briefly in an ice bath. To the mixture was added dropwise benzoyl chloride (0.116 mL, 1 mmol) and the resulting mixture was stirred 18 h at room temperature, filtered and evaporated to an oil.
25 Crystallization as the oxalate salt from ethyl acetate/methanol provided 0.284 g colorless crystals. Mp 105°C. Mass spectrum, $m^+ = 419$. Exact mass theory, 419.2321; found, 419.2315.

30

-21-

Preparation 4

Preparation of 1-(2-aminoethyl)-4-benzylpiperidine

4-Benzylpiperidine (5.30 mL, 30 mmol), N-(2-bromoethyl)phthalimide (7.6 g, 30 mmol) and sodium carbonate (7.95 g, 75 mmol) were heated together in 150 mL dimethylformamide at 100°C for 18 h. Evaporation of the dimethylformamide, dilution with water and extraction with ethyl acetate followed by water washing, brine washing and drying, provided, after evaporation, 11.61 g oil. Crystallization as the tosylate salt from ethanol provided 10.39 g colorless crystals. Mp 194-196°C. Mass spectrum, $m^+ = 348$. Anal (C₂₉H₃₂N₂O₅S) theory C, 66.90; H, 6.20; N, 5.38; found C, 66.68; H, 6.40; N, 5.16.

The intermediate above as the free base (5.05 g, 14 mmol) was stirred in 225 mL ethanol while 5.0 mL of hydrazine hydrate was added. This mixture was heated at reflux temperature for 4 h. After cooling, the mixture was filtered and the filtrate was evaporated to a residue. This residue was carefully diluted with a 1N sodium hydroxide solution, followed by extractions with diethyl ether, drying and evaporation to give 3.13 g of oil. Mass spectrum, $m^+ = 218$.

25

Example 19

Preparation of N-[2-(4-benzyl-1-piperidinyl)ethyl]-1H-indazole-3-carboxamide

Same procedure followed as described in Example 5. The following reactants and amounts were used: 1H-indazole-3-carboxylic acid (1.62 g, 10 mmol), 1,1'-carbonyldiimidazole (1.62 g, 10 mmol) and the intermediate from Preparation 4 (2.18 g, 10 mmol). The ethyl acetate extracts were evaporated to a solid. Addition of cyclohexane and filtration provided 3.52 g of solid. Mass spectrum, $m^+ = 363$.

-22-

Example 20

Preparation of N-[2-(4-benzyl-1-piperidinyl)ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide oxalate

5 Same procedure followed as described in Example 2. The following amounts were used: Product from Example 19 (3.50 g, 9.7 mmol), sodium hydride (0.390 g, 9.7 mmol, as a 60% mineral oil dispersion) and 2-iodopropane (1.07 mL, 10.7 mmol). The ethyl acetate extracts were evaporated to 10 4.30 g oil. Flash chromatography [silica gel, methylene chloride/methanol (93/7)] yielded 2.52 g oil. Crystallization as the oxalate salt from ethanol provided 2.51 g of colorless crystals. Mp 149°C. Mass spectrum, $m^+ = 404$. Anal (C₂₇H₃₄N₄O₅) theory C, 65.57; H, 6.93; N, 11.33; found C, 65.32; H, 6.86; N, 11.48.

Preparation 5

Preparation of 2-(2-aminoethyl)-1,2,3,4-tetrahydroisoquinoline

20 1,2,3,4-Tetrahydroisoquinoline (3.76 mL, 30 mmol), N-(2-bromoethyl)phthalimide (7.6 g, 30 mmol) and sodium carbonate (8.0 g, 75 mmol) were heated together in 150 mL dimethylformamide at 100°C for 18 h. Evaporation of the 25 dimethylformamide, dilution with water and extraction with ethyl acetate followed by water washing, brine washing and drying, provided, after evaporation, 10.46 g oil. Crystallization as the tosylate salt from ethanol provided 10.30 g colorless crystals. Mp 196-198°C. Mass spectrum, 30 $m^+ = 306$. Anal (C₂₆H₂₆N₂O₅S) theory C, 65.26; H, 5.48; N, 5.85; found C, 65.37; H, 5.45; N, 5.95.

The intermediate above as the free base (3.06 g, 10 mmol) was stirred in 200 mL ethanol while 5.0 mL of hydrazine hydrate was added. This mixture was heated at 35 reflux temperature for 4 h. After cooling, the mixture was filtered and the filtrate was evaporated to a residue. This residue was carefully diluted with a 1N sodium hydroxide

-23-

solution, followed by extraction with diethyl ether, drying and evaporation to give 1.62 g of oil. Mass spectrum, $m^+ = 176$.

5

Example 21

Preparation of N-[2-(1,2,3,4-tetrahydro-2-isoquinolinyl)ethyl]-1H-indazole-3-carboxamide

Same procedure followed as described in Example 5.

10

The following amounts were used: 1H-indazole-3-carboxylic acid (1.49 g, 9.2 mmol), 1,1'-carbonyldiimidazole (1.49 g, 9.2 mmol) and the intermediate from Preparation 5 (1.62 g, 9.2 mmol). The ethyl acetate extracts were evaporated to a solid. Addition of cyclohexane and filtration provided

15

2.73 g of solid. Mass spectrum, $m^+ = 321$.

Example 22

Preparation of N-[2-(1,2,3,4-tetrahydro-2-isoquinolinyl)ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide oxalate

20

Same procedure followed as described in Example 2.

The following amounts were used: Product from Example 21 (2.70 g, 8.5 mmol), sodium hydride (0.340 g, 8.5 mmol, as a 60% mineral oil dispersion) and 2-iodopropane (0.94 mL, 9.4 mmol). The ethyl acetate extracts were evaporated to 3.28 g oil. Flash chromatography [silica gel, methylene chloride/methanol (97/3)] yielded 2.62 g oil.

25

Crystallization as the oxalate salt from ethanol provided 2.47 g of colorless crystals. Mp 191°C. Mass spectrum, $m^+ = 362$. Anal (C₂₄H₂₈N₄O₅) theory C, 63.70; H, 6.24; N, 12.38; found C, 63.96; H, 6.47; N, 12.26.

30

-24-

Example 23

Preparation of N-[2-(4-amino-1-piperidinyl)ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide dioxalate

5 The product from Example 8, as the free base (8.71 g, 18.8 mmol), was reacted with hydrogen gas in the presence of 5% Pd/C (25°C/18h/60 PSI) in an ethanol solution. After filtering the catalyst, the ethanol was evaporated to 5.0 g oil. Crystallization as the dioxalate salt from
10 methanol/water provided colorless crystals. Mp 232°C. Mass spectrum, $m^+ = 329$. Anal (C₂₂H₃₁N₅O₉) theory C, 51.86; H, 6.13; N, 13.75; found C, 51.61; H, 6.04; N, 13.48.

Example 24

15 Preparation of N-[2-(4-methylsulfonylamino-1-piperidinyl)ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide oxalate

20 The product from Example 23, as the free base (0.330 g, 1 mmol) and triethylamine (0.15 mL, 1.05 mmol) were stirred in 10.0 mL tetrahydrofuran and cooled briefly in an ice bath. To the mixture was added dropwise methanesulfonyl chloride (0.08 mL, 1 mmol) and the resulting mixture was stirred 18 h at room temperature. The mixture was filtered
25 and the filtrate was evaporated to 0.401 g oil. Flash chromatography [silica gel, methylene chloride/methanol (90/10)] yielded 0.147 g oil. Crystallization as the oxalate salt from ethyl acetate/methanol provided 0.149 g colorless crystals. Mp 204°C. Mass spectrum, $m^+ = 407$. Exact mass
30 theory, 408.2069; found, 408.2066.

Example 25

Preparation of N-[2-(4-benzoylamino-1-piperidinyl)ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide oxalate

35

 The product from Example 23, as the free base (0.330 g, 1 mmol) and triethylamine (0.15 mL, 1.05 mmol) were

-25-

stirred in 10.0 mL tetrahydrofuran and cooled briefly in an ice bath. To the mixture was added dropwise benzoyl chloride (0.116 mL, 1 mmol) and the resulting mixture was stirred 18 h at room temperature and filtered and the filtrate was
5 evaporated to 0.498 g oil. Crystallization as the oxalate salt from ethyl acetate/methanol provided 0.265 g colorless crystals. Mp 130°C. Mass spectrum, $m^+ = 433$. Anal (C₂₇H₃₃N₅O₆) theory C, 61.94; H, 6.35; N, 13.38; found C, 61.73; H, 6.35; N, 13.33.

Example 26

Preparation of N-[2-(4-benzylcarbonylamino-1-piperidinyl)-ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide oxalate

15 The product from Example 23, as the free base (0.310 g, 0.94 mmol) and triethylamine (0.13 mL, 0.94 mmol) were stirred in 10.0 mL tetrahydrofuran and cooled briefly in an ice bath. To the mixture was added dropwise phenylacetyl chloride (0.12 mL, 0.94 mmol) and the resulting mixture was
20 stirred 18 h at room temperature and filtered, and the filtrate was evaporated to an oil. Crystallization as the oxalate salt from ethyl acetate/methanol provided 0.176 g colorless crystals. Mp 168°C. Mass spectrum, $m^+ = 447$. Anal (C₂₈H₃₅N₅O₆) theory C, 62.56; H, 6.56; N, 13.03; found
25 C, 62.61; H, 6.65; N, 12.83.

Example 27

Preparation of N-[2-(4-(1-adamantylcarbonylamino)-1-piperidinyl)ethyl]-1-(2-propyl)-1H-indazole-3-
30 carboxamide oxalate

The product from Example 23, as the free base (0.330 g, 1 mmol) and triethylamine (0.15 mL, 1.05 mmol) were stirred in 10.0 mL tetrahydrofuran and cooled briefly in an
35 ice bath. To the mixture was added, in portions, 1-adamantanecarbonyl chloride (0.199 g, 1 mmol) and the resulting mixture was stirred 18 h at room temperature and

-26-

filtered, and the filtrate was evaporated to 0.565 g oil. Crystallization as the oxalate salt from ethyl acetate/methanol provided 0.267 g colorless crystals. Mp 228°C. Mass spectrum, $m^+ = 491$. Anal ($C_{31}H_{43}N_5O_6$) theory C, 64.01; H, 7.45; N, 12.04; found C, 63.89; H, 7.53; N, 12.12.

Example 28

Preparation of N-[2-(4-acetylamino-1-piperidinyl)ethyl]-
1-(2-propyl)-1H-indazole-3-carboxamide oxalate

The product from Example 23, as the free base (0.330 g, 1 mmol) and triethylamine (0.15 mL, 1.05 mmol) were stirred in 10.0 mL tetrahydrofuran and cooled briefly in an ice bath. To the mixture was added dropwise acetyl chloride (0.071 mL, 1 mmol) and the resulting mixture was stirred 18 h at room temperature and filtered, and the filtrate was evaporated to 0.360 g oil. Crystallization as the oxalate salt from ethyl acetate/methanol provided 0.243 g colorless crystals. Mp 176°C. Mass spectrum, $m^+ = 371$. Anal ($C_{22}H_{31}N_5O_6$) theory C, 57.25; H, 6.77; N, 15.17; found C, 56.95; H, 6.74; N, 14.99.

Example 29

Preparation of N-[2-(4-propionylamino-1-piperidinyl)ethyl]-
1-(2-propyl)-1H-indazole-3-carboxamide oxalate

The product from Example 23, as the free base (0.310 g, 0.94 mmol) and triethylamine (0.13 mL, 0.94 mmol) were stirred in 10.0 mL tetrahydrofuran and cooled briefly in an ice bath. To the mixture was added dropwise propionyl chloride (0.08 mL, 0.94 mmol) and the resulting mixture was stirred 18 h at room temperature and filtered, and the filtrate was evaporated to an oil. Crystallization as the oxalate salt from ethyl acetate/methanol provided 0.168 g colorless crystals. Mp 169°C. Mass spectrum, $m^+ = 385$.

-27-

Anal (C₂₃H₃₃N₅O₆) theory C, 58.09; H, 6.99; N, 14.73; found C, 57.79; H, 6.93; N, 14.46.

Example 30

5 Preparation of N-[2-(4-butyrylamino-1-piperidinyl)ethyl]-
1-(2-propyl)-1H-indazole-3-carboxamide oxalate

10 The product from Example 23, as the free base
(0.330 g, 1 mmol) and triethylamine (0.15 mL, 1.05 mmol) were
stirred in 10.0 mL tetrahydrofuran and cooled briefly in an
ice bath. To the mixture was added dropwise butyryl chloride
(0.1 mL, 1 mmol) and the resulting mixture was stirred 18 h
at room temperature and filtered, and the filtrate was
15 evaporated to 0.389 g oil. Crystallization as the oxalate
salt from ethyl acetate/methanol provided 0.149 g colorless
crystals. Mp 122°C. Mass spectrum, m⁺ = 399. Anal
(C₂₄H₃₅N₅O₆) theory C, 58.88; H, 7.21; N, 14.32; found C,
58.60; H, 7.15; N, 14.30.

20 Example 31

Preparation of N-[2-(4-valerylamino-1-piperidinyl)ethyl]-
1-(2-propyl)-1H-indazole-3-carboxamide

25 The product from Example 23, as the free base
(0.330 g, 1 mmol) and triethylamine (0.15 mL, 1.05 mmol) were
stirred in 10.0 mL tetrahydrofuran and cooled briefly in an
ice bath. To the mixture was added dropwise valeryl chloride
(0.12 mL, 1 mmol) and the resulting mixture was stirred 18 h
at room temperature and filtered, and the filtrate was
30 evaporated to 0.385 g oil. Crystallization from diethyl
ether provided 0.176 g colorless crystals. Mp 107-109°C.
Mass spectrum, m⁺ = 413. Anal (C₂₃H₃₅N₅O₂) theory C, 66.80;
H, 8.53; N, 16.93; found C, 66.59; H, 8.66; N, 17.04.

-28-

Example 32

Preparation of N-[2-(4-isobutyrylamino-1-piperidinyl)ethyl]-
1-(2-propyl)-1H-indazole-3-carboxamide oxalate

5 The product from Example 23, as the free base
(0.330 g, 1 mmol) and triethylamine (0.15 mL, 1.05 mmol) were
stirred in 10.0 mL tetrahydrofuran and cooled briefly in an
ice bath. To the mixture was added dropwise isobutyryl
10 chloride (0.10 mL, 1 mmol) and the resulting mixture was
stirred 18 h at room temperature and filtered, and the
filtrate was evaporated to 0.417 g oil. Crystallization as
the oxalate salt from 2-propanol provided 0.194 g colorless
crystals. Mp 193°C. Mass spectrum, $m^+ = 399$. Anal
(C₂₄H₃₅N₅O₆) theory C, 58.88; H, 7.21; N, 14.30; found C,
15 58.60; H, 6.95; N, 14.11.

Example 33

Preparation of N-[2-(4-trimethylacetylamino-1-piperidinyl)-
ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide oxalate

20 The product from Example 23, as the free base
(0.330 g, 1 mmol) and triethylamine (0.15 mL, 1.05 mmol) were
stirred in 10.0 mL tetrahydrofuran and cooled briefly in an
ice bath. To the mixture was added dropwise trimethylacetyl
25 chloride (0.12 mL, 1 mmol) and the resulting mixture was
stirred 18 h at room temperature and filtered, and the
filtrate was evaporated to 0.384 g oil. Crystallization as
the oxalate salt from 2-propanol provided 0.297 g colorless
crystals. Mp 194°C. Mass spectrum, $m^+ = 413$. Anal
30 (C₂₅H₃₇N₅O₆) theory C, 59.63; H, 7.41; N, 13.91; found C,
59.47; H, 7.62; N, 13.63.

-29-

Example 34

Preparation of N-[2-(4-benzylaminocarbonylamino)-1-piperidinyl)ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide oxalate

5

The product from Example 23, as the free base (0.330 g, 1 mmol) was stirred in 8 mL tetrahydrofuran and cooled in an ice bath to 10°C. To the mixture was added dropwise benzyl isocyanate (0.12 mL, 1 mmol) and the resulting mixture was stirred 1.5 h at room temperature and evaporated to an oil. Crystallization as the oxalate salt from ethanol provided 0.319 g colorless crystals. Mp 168°C. Mass spectrum, $m^+ = 463$. Exact mass theory, 463.2821; found, 463.2838.

10

15

Example 35

Preparation of N-[2-(4-phenylaminocarbonylamino)-1-piperidinyl)ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide oxalate

20

The product from Example 23, as the free base (0.330 g, 1 mmol) was stirred in 8 mL tetrahydrofuran and cooled in an ice bath to 10°C. To the mixture was added dropwise phenyl isocyanate (0.11 mL, 1 mmol) and the resulting mixture was stirred 1.5 h at room temperature and evaporated to an oil. Crystallization as the oxalate salt from ethanol provided 0.299 g colorless crystals. Mp 198°C. Mass spectrum, $m^+ = 449$. Anal (C₂₇H₃₄N₆O₆) theory C, 60.21; H, 6.36; N, 15.60; found C, 60.42; H, 6.60; N, 15.47.

25

30

Example 36

Preparation of N-[2-(4-(4-fluorophenylaminocarbonylamino)-1-piperidinyl)ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide oxalate

35

The product from Example 23, as the free base (0.330 g, 1 mmol) was stirred in 8 mL tetrahydrofuran and

-30-

cooled in an ice bath to 10°C. To the mixture was added dropwise 4-fluorophenyl isocyanate (0.11 mL, 1 mmol) and the resulting mixture was stirred 1.5 h at room temperature and filtered, and the filtrate was evaporated to an oil.

5 Crystallization as the oxalate salt from ethyl acetate/methanol provided 0.147 g colorless crystals. Mp 158°C. Mass spectrum, $m^+ = 466$. Anal (C₂₇H₃₃FN₆O₆) theory C, 58.27; H, 5.98; N, 15.10; found C, 58.48; H, 6.23; N, 14.94.

10

Example 37

Preparation of N-[2-(4-(3-hydroxy-1-adamantylcarbonylamino)-1-piperidinyl)ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide oxalate

15

A mixture of 1.07 g (5.45 mmol) of 3-hydroxy-1-adamantylcarboxylic acid and 0.88 g (5.45 mmol) of 1,1'-carbonyldiimidazole in 10 mL of dimethylformamide was stirred for 2 hours at ambient temperature. To this solution was dropwise added 1.80 g (5.45 mmol) of the product of Example 23 in 7 mL of dimethylformamide. The reaction was stirred for 18 hours and then concentrated in vacuo, diluted with dichloromethane and solids removed by filtration. The crude product was purified by chromatography (silica, 9:1 dichloromethane-methanol) to provide 1.30 g (47%) of the desired product as a foam. Further treatment of the product with 0.23 g (2.62 mmol) of oxalic acid in 20 mL of ethanol provided, upon concentration of the solution, 1.51 g of the oxalate salt (LSN343031). ¹H NMR (500 MHz, DMSO-d₆) δ 8.51 (t, 1H), 8.19 (d, 1H), 7.9 (br s, 3H), 7.78 (d, 1H), 7.44 (t, 1H), 7.40 (d, 1H), 7.27 (t, 1H), 5.06 (m, 1H), 3.84 (m, 1H), 3.72 (m, 2H), 3.52 (m, 2H), 3.24 (br t, 2H), 3.07 (br t, 2H), 2.11 (br s, 2H), 1.82 (m, 4H), 1.64 (m, 6H), 1.55 (m, 10H), 1.48 (br s, 2H).

30

-31-

Example 38

Preparation of N-[2-(4-(4-hydroxy-1-adamantylcarbonylamino)-1-piperidiny)ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide oxalate

5

A mixture of 0.50 g (2.55 mmol) of 4-hydroxy-1-adamantylcarboxylic acid and 0.44 g (2.71 mmol) of 1,1'-carbonyldiimidazole in 10 mL of dimethylformamide was stirred for 2 hours at ambient temperature. To this solution was
10 dropwise added 0.90 g (2.75 mmol) of the product of Example 23 in 7 mL of dimethylformamide. The reaction was stirred for 18 hours and then concentrated in vacuo, diluted with dichloromethane and solids removed by filtration. The crude product was purified by chromatography (silica, 9:1
15 dichloromethane-methanol) to provide 0.71 g (55%) of the desired product as a foam. Further treatment of 500 mg of the product with 88 mg of oxalic acid in 15 mL of ethanol provided, upon concentration of the solution, 580 mg of the oxalate salt (LSN343032). ¹H NMR (300 MHz, DMSO-d₆) δ 8.47
20 (t, 1H), 8.11 (d, 1H), 7.75 (d, 1H), 7.40 (t, 1H), 7.28 (d, 1H), 7.21 (t, 1H), 6.3 (br s, 3H), 5.04 (m, 1H), 3.74 (m, 1H), 3.59 (m, 3H), 3.40 (m, 2H), 3.13 (m, 2H), 2.95 (m, 2H), 1.95 (d, 2H), 1.69 (m, 13H), 1.47 (d, 6H), 1.25 (d, 2H).

25 Treatment

Representative compounds of the present invention have been biologically tested to demonstrate their interaction with the 5-HT₄ receptor. The test was carried out in esophagus smooth muscle, freshly removed from male
30 Wistar rats weighing 250-300 g each. The rats were killed by cervical dislocation, and the esophagus was removed and dissected free of connective tissue. The esophagi were used as longitudinal preparations -- obtaining two preparations from each animal. The tissues were tied with thread at each
35 end with the lower end being tied to a stationary glass rod and the upper end to a force transducer.

-32-

Tissues were mounted in organ baths containing 10 mL of modified Krebs' solution of the following composition (millimolar) NaCl 118.2; KCl 4.6; $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ 1.6; KH_2PO_4 1.2; MgSO_4 1.2; dextrose 10.0; and NaHCO_3 24.8. Tissue bath solutions were maintained at 37°C and aerated with 95% O_2 -5% CO_2 . Tissues were placed under optimum resting force, 1 g, and were allowed to equilibrate for 1 hr before exposure to drugs. Isometric contractions were recorded as changes in grams of force on the Modular Instruments Inc. (Malvern, Pa) model M4000 data acquisition system with Sensotec (Columbus, Ohio) model MBL 5514-02 transducers.

For studies with partial agonists or antagonists, tissues were preincubated with vehicle or antagonist for 45 min. All drugs were prepared daily in deionized water and kept on ice during the course of the experiment. The tissues were contracted by incubation with 10^{-7} - 10^{-5}M carbamylcholine, and were relaxed by the addition of serotonin at 10^{-8} - 10^{-10}M , which treatment relaxed the tissue and reduced the contraction caused by carbamylcholine. Addition of a compound of the present invention antagonized the serotonin response and reduced the observed relaxations of the tissue. Repeated tests of each compound at various concentrations were carried out, and the concentration that caused a two-fold shift of the relaxation curve was calculated. That concentration is reported here as the negative logarithm. In each case, the SEM of the data has been calculated and is shown below, as is the number of experiments carried out with each compound.

30	Compound of Example No.	<u>-Log K_B</u>
	1	7.5±.01 (4)
	2	8.0±.3 (9)
35	4	8.1±.4 (3)
	6	8.2±.1 (5)
	8	8.8±.2 (15)

-33-

	10	7.7±.1(3)
	12	8.0±.6(4)
	14	7.6±.2(7)
	16	8.0±.3(6)
5	18	7.5±.4(4)
	20	7.3±.2(5)
	22	8.0±.3(4)
	23	6.8±1(4)
	24	7.9±.6(4)
10	25	8.6±.2(8)
	26	8.4±.2(8)
	27	9.9±.4(6)
	28	8.3±.3(4)
	29	8.5±.2(3)
15	30	7.8±.3(4)
	31	7.7±.4(4)
	32	8.6±.2(5)
	33	8.5±.3(3)
	34	8.3±.4(3)
20	35	8.0±.2(3)
	36	7.6±.05(3)
	37	8.9
	38	8.7

25 The above data demonstrate that the compounds of the present invention have extremely high affinity for the 5-HT₄ receptor. Further, it has been found that the compounds of the present invention have a usefully long duration of action *in vivo*, particularly as compared to

30 cisapride, a presently known compound with high affinity at the 5-HT₄ receptor. It is also remarkable that compounds of the present invention are markedly more potent in their affinities at the 5-HT₄ receptor than in other activities and

35 at other receptors; the selectivity is often proved by concentration differences amounting to two or even more orders of magnitude to achieve the same binding potency.

-34-

Accordingly, the methods of the present invention are very potent in affecting the 5-HT₄ receptor, and particularly in providing an antagonist effect at that receptor. The methods of the present invention are carried out by administering a compound as described above in an effective dose to a subject in need of such an effect at the 5-HT₄ receptor, or in need of treatment or prophylaxis of a dysfunction or disorder of the 5-HT₄ receptor. An effective dose, in the contemplation of the present invention, is an amount of compound which is adequate to provide the desired effect, or to provide treatment for the disorder. The compounds are effective, in general, at quite low doses, and are effective over a substantial dosage range. Effective doses will normally fall within the range from about 0.001 to about 30 mg/kg/day of body weight. As usual in pharmaceutical treatments, the daily dose may be administered in a single bolus, or in divided doses, at the judgment of the physician in charge. A more preferred range of doses is from about 0.1 to about 3.0 mg/kg/day. It will be understood by the reader that the dose for a given subject is always to be set by the judgment of the attending physician, and that the dose is subject to modification based on the size of the patient, the lean or fat nature of the subject, the characteristics of the particular compound chosen, the intensity of the subject's symptoms or disease involvement, and perhaps psychological factors which may affect the subject's physiological responses.

The invention is effective in mammals which possess a 5-HT₄ receptor; the preferred subject is the human.

As briefly mentioned above, a variety of physiological functions have been shown to be influenced by the 5-HT₄ receptor. Accordingly, the methods of the present invention include methods of treatment or prophylaxis of pathologies of the central nervous system such as anxiety, pain, depression, schizophrenia, memory disorders, and dementia; pathologies of the gastrointestinal tract such as irritable bowel syndrome, nausea, gastroesophageal reflux

-35-

disease, dyspepsia, gastrointestinal motility disorders, and constipation; cardiovascular disorders such as atrial fibrillation, arrhythmias and tachycardia; and genitourinary disorders such as urinary retention, urinary incontinence, and pain on urination. The dosage rates for the treatment of the foregoing disorders are those which have just been mentioned as effective for blocking the 5-HT₄ receptor, since treatment or prophylaxis is obtained by activity at that receptor.

Pharmaceutical Compositions

It is customary to formulate pharmaceuticals for administration, to provide control of the dosage and stability of the product in shipment and storage, and the usual methods of formulation are entirely applicable to the compounds of Formula I. Such compositions, comprising at least one pharmaceutically acceptable carrier, are valuable and novel because of the presence of the compounds of Formula I therein. Although pharmaceutical chemists are well aware of many effective ways to formulate pharmaceuticals, which technology is applicable to the present compounds, some discussion of the subject will be given here for the convenience of the reader.

The usual methods of formulation used in pharmaceutical science and the usual types of compositions may be used, including tablets, chewable tablets, capsules, solutions, parenteral solutions, intranasal sprays or powders, troches, suppositories, transdermal patches and suspensions. In general, compositions contain from about 0.5% to about 50% of the compound in total, depending on the desired dose and the type of composition to be used. The amount of the compound, however, is best defined as the effective amount, that is, the amount of each compound which provides the desired dose to the patient in need of such treatment. The activity of the compounds do not depend on the nature of the composition, so the compositions are chosen and formulated solely for convenience and economy. Any

-36-

compound may be formulated in any desired form of composition. Some discussion of different compositions will be provided, followed by some typical formulations.

5 Capsules are prepared by mixing the compound with a suitable diluent and filling the proper amount of the mixture in capsules. The usual diluents include inert powdered substances such as starch of many different kinds, powdered cellulose, especially crystalline and microcrystalline cellulose, sugars such as fructose, mannitol and sucrose,
10 grain flours and similar edible powders.

Tablets are prepared by direct compression, by wet granulation, or by dry granulation. Their formulations usually incorporate diluents, binders, lubricants and disintegrators as well as the compound. Typical diluents
15 include, for example, various types of starch, lactose, mannitol, kaolin, calcium phosphate or sulfate, inorganic salts such as sodium chloride and powdered sugar. Powdered cellulose derivatives are also useful. Typical tablet binders are substances such as starch, gelatin and sugars
20 such as lactose, fructose, glucose and the like. Natural and synthetic gums are also convenient, including acacia, alginates, methylcellulose, polyvinylpyrrolidone and the like. Polyethylene glycol, ethylcellulose and waxes can also serve as binders.

25 A lubricant is necessary in a tablet formulation to prevent the tablet and punches from sticking in the die. The lubricant is chosen from such slippery solids as talc, magnesium and calcium stearate, stearic acid and hydrogenated vegetable oils.

30 Tablet disintegrators are substances which swell when wetted to break up the tablet and release the compound. They include starches, clays, celluloses, algin and gums. More particularly, corn and potato starches, methylcellulose, agar, bentonite, wood cellulose, powdered natural sponge,
35 cation-exchange resins, alginic acid, guar gum, citrus pulp and carboxymethylcellulose, for example, may be used, as well as sodium lauryl sulfate.

-37-

Enteric formulations are often used to protect an active ingredient from the strongly acidic contents of the stomach. Such formulations are created by coating a solid dosage form with a film of a polymer which is insoluble in acidic environments, and soluble in basic environments. Exemplary films are cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate.

Tablets are often coated with sugar as a flavor and sealant, or with film-forming protecting agents to modify the dissolution properties of the tablet. The compounds may also be formulated as chewable tablets, by using large amounts of pleasant-tasting substances such as mannitol in the formulation, as is now well-established practice. Instantly dissolving tablet-like formulations are also now frequently used to assure that the patient consumes the dosage form, and to avoid the difficulty in swallowing solid objects that bothers some patients.

When it is desired to administer the combination as a suppository, the usual bases may be used. Cocoa butter is a traditional suppository base, which may be modified by addition of waxes to raise its melting point slightly. Water-miscible suppository bases comprising, particularly, polyethylene glycols of various molecular weights are in wide use, also.

Transdermal patches have become popular recently. Typically they comprise a resinous composition in which the drugs will dissolve, or partially dissolve, which is held in contact with the skin by a film which protects the composition. Many patents have appeared in the field recently. Other, more complicated patch compositions are also in use, particularly those having a membrane pierced with numerous pores through which the drugs are pumped by osmotic action.

The following typical formulae are provided for the interest and information of the pharmaceutical scientist.

-38-

Formulation 1

Hard gelatin capsules are prepared using the following ingredients:

5		Quantity
		<u>(mg/capsule)</u>
	Example 27	20 mg
	Starch, dried	200 mg
	Magnesium stearate	<u>10 mg</u>
10	Total	230 mg-

Formulation 2

A tablet is prepared using the ingredients below:

15		Quantity
		<u>(mg/capsule)</u>
	Example 28	10 mg
	Cellulose, microcrystalline	400 mg
	Silicon dioxide, fumed	10 mg
	Stearic acid	<u>5 mg</u>
20	Total	425 mg

The components are blended and compressed to form tablets each weighing 425 mg.

Formulation 3

Tablets, each containing 10 mg of active ingredient, are made as follows:

30		Quantity
		<u>(mg/capsule)</u>
	Example 8	10 mg
	Starch	45 mg
	Microcrystalline cellulose	35 mg
35	Polyvinylpyrrolidone	
	(as 10% solution in water)	4 mg

-39-

Sodium carboxymethyl starch	4.5 mg
Magnesium stearate	0.5 mg
Talc	<u>1 mg</u>
Total	100 mg

5 The active ingredient, starch and cellulose are passed
through a No. 45 mesh U.S. sieve and mixed thoroughly. The
aqueous solution containing polyvinylpyrrolidone is mixed
10 with the resultant powder, and the mixture then is passed
through a No. 14 mesh U.S. sieve. The granules so produced
are dried at 50°C and passed through a No. 18 mesh U.S.
Sieve. The sodium carboxymethyl starch, magnesium stearate
and talc, previously passed through a No. 60 mesh U.S. sieve,
15 are then added to the granules which, after mixing, are
compressed on a tablet machine to yield tablets each weighing
100 mg.

Formulation 4

20 Capsules, each containing 30 mg of active
ingredient, are made as follows:

	Quantity (mg/capsule)
25 Example 11	30 mg
Starch	59 mg
Microcrystalline cellulose	59 mg
Magnesium stearate	<u>2 mg</u>
Total	150 mg

30 The active ingredient, cellulose, starch, and
magnesium stearate are blended, passed through a No. 45 mesh
U.S. sieve, and filled into hard gelatin capsules in 150 mg
quantities.

-40-

Formulation 5

Suppositories, each containing 5 mg of active ingredient, are made as follows:

5		Quantity
		<u>(mg/capsule)</u>
	Example 21	5 mg
	Saturated fatty acid glycerides	<u>2.000 mg</u>
	Total	2,005 mg

10

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.

15

Formulation 6

Suspensions, each containing 10 mg of active ingredient per 5 ml dose, are made as follows:

20

		Quantity
		<u>(mg/capsule)</u>
	Example 6	10 mg
	Sodium carboxymethylcellulose	50 mg
25	Syrup	1.25 ml
	Benzoic acid solution	0.10 ml
	Flavor	q.v.
	Color	q.v.
	Purified water to total	5 ml

30

The active ingredient is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethylcellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with a portion of the water and added, with stirring. Sufficient water is then added to produce the required volume.

35

-41-

Formulation 7

An intravenous formulation may be prepared as follows:


5

	Quantity <u>(mg/capsule)</u>
Example 32	10 mg
Isotonic saline	1,000 ml

-42-

We claim:

1. A compound of the formula



wherein:

R is hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl;R¹ is hydrogen, halo, C₁-C₄ alkyl, hydroxy, C₁-C₄ alkoxy or alkylthio, cyano, trifluoromethyl, carboxamido, mono- or di(C₁-C₄ alkyl)carboxamido;

m, n and o are independently 0-5, provided that the sum of m, n and o is 2-5;

R² is hydrogen or C₁-C₄ alkyl;R³ and R⁴ combine with the nitrogen atom to which they are attached to form 1-pyrrolidinyl, 1-piperazinyl, 1,2,3,4-tetrahydro-isoquinolinyl, 2,3-dihydro-1-indolinyl, 4-morpholinyl, 1-piperidinyl or 1-hexamethyleneiminyl, substituted with

phenyl, naphthyl, (phenyl or naphthyl)(C₁-C₃ alkyl), (phenyl or naphthyl)(C₁-C₃ alkanoyl), amino, mono- or di(C₁-C₄ alkyl)amino, or a group of the formula -NH-Y-R⁵; provided that a piperazinyl or morpholinyl group may not be substituted with amino, mono- or di(C₁-C₄ alkyl)amino, or -NH-Y-R⁵;

wherein a phenyl or naphthyl group is unsubstituted or substituted with 1-3 halo, C₁-C₃ alkyl or C₁-C₃ alkoxy groups;

Y is carbonyl, sulfonyl, aminocarbonyl or oxycarbonyl;

-43-

R⁵ is C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₆-C₁₁ bicyclo- or tricycloalkyl, (phenyl or naphthyl)(C₁-C₃ alkyl), phenyl or naphthyl;

wherein a cycloalkyl, bicyclo- or tricycloalkyl, phenyl or naphthyl group is unsubstituted or substituted with 1-3 hydroxy, halo, C₁-C₃ alkyl or C₁-C₃ alkoxy groups;

or a pharmaceutically acceptable salt thereof.

2. A compound of Claim 1 wherein m + n ≠ 0 is 2-4.

3. A compound of Claim 2 wherein R is hydrogen or alkyl.

4. A compound of Claim 3 wherein R¹ is hydrogen, halo, alkyl or alkoxy.

5. A compound of Claim 4 wherein the group formed by the combination of R³ and R⁴ with the nitrogen atom to which they are attached is substituted with phenyl, naphthyl, (phenyl or naphthyl)(C₁-C₃ alkyl), or (phenyl or naphthyl)(C₁-C₃ alkanoyl).

6. A compound of Claim 4 wherein the group formed by the combination of R³ and R⁴ with the nitrogen atom to which they are attached is substituted with a group of the formula -NH-Y-R⁵.

7. The compound of Claim 1 which is N-[2-(4-(3-hydroxy-1-adamantylcarbonylamino)-1-piperidinyl)ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide or N-[2-(4-(4-hydroxy-1-adamantylcarbonylamino)-1-piperidinyl)ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.

8. The compound of Claim 1 which is N-[2-(4-benzyloxycarbonylamino-1-piperidinyl)ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.

-44-

9. The compound of Claim 1 which is N-[2-(4-acetylamino-1-piperidinyl)ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.

5 10. The compound of Claim 1 which is N-[2-(4-(1-adamantylcarbonylamino)-1-piperidinyl)ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.


10 11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1.

12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 3.

15 13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 4.

14. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of Claim 10.

20 15. A method of affecting the 5-HT₄ receptor comprising administering to a subject in need of such treatment an effective amount of a compound of the formula



25

R is hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl;

R¹ is hydrogen, halo, C₁-C₄ alkyl, hydroxy, C₁-C₄ alkoxy or alkylthio, cyano, trifluoromethyl, carboxamido, mono- or di(C₁-C₄ alkyl)carboxamido;

30 m, n and o are independently 0-5, provided that the sum of m, n and o is 2-5;

-45-

R² is hydrogen or C₁-C₄ alkyl;

R³ and R⁴ combine with the nitrogen atom to which they are attached to form 1-pyrrolidinyl, 1-piperazinyl, 1,2,3,4-tetrahydro-2-isoquinolinyl, 2,3-dihydro-1-indolinyl, 4-morpholinyl, 1-piperidinyl or 1-hexamethyleneiminyl, unsubstituted or substituted with

phenyl, naphthyl, (phenyl or naphthyl)(C₁-C₃ alkyl), (phenyl or naphthyl)(C₁-C₃ alkanoyl), amino, mono- or di(C₁-C₄ alkyl)amino, or a group of the formula -NH-Y-R⁵; provided that a piperazinyl or morpholinyl group may not be substituted with amino, mono- or di(C₁-C₄ alkyl)amino, or -NH-Y-R⁵;

wherein a phenyl or naphthyl group is unsubstituted or substituted with 1-3 halo, C₁-C₃ alkyl or C₁-C₃ alkoxy groups;

Y is carbonyl, sulfonyl, aminocarbonyl or oxycarbonyl;

R⁵ is C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₆-C₁₁ bicyclo- or tricycloalkyl, (phenyl or naphthyl)(C₁-C₃ alkyl), phenyl or naphthyl;

wherein a cycloalkyl, bicyclo- or tricycloalkyl, phenyl or naphthyl group is unsubstituted or substituted with 1-3 hydroxy, halo, C₁-C₃ alkyl or C₁-C₃ alkoxy groups;

or a pharmaceutically acceptable salt thereof.


16. A method of Claim 15 wherein the compound is a compound wherein m + n + o is 2-4, and R is hydrogen or alkyl.

17. A method of Claim 16 wherein the compound is N-[2-(4-(1-adamantylcarboxamido)-1-piperidinyl)ethyl]-1-(2-propyl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.

18. A method of providing treatment or prophylaxis for anxiety, pain, depression, schizophrenia, memory disorders, dementia, irritable bowel syndrome, nausea,

-46-

gastroesophageal reflux disease, dyspepsia, gastrointestinal motility disorders, constipation, atrial fibrillation, arrhythmias, tachycardia, urinary retention, urinary incontinence, or pain on urination, comprising administering to a subject in need of such treatment or prophylaxis an effective amount of a compound of the formula



10 wherein:

R is hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl;

R¹ is hydrogen, halo, C₁-C₄ alkyl, hydroxy, C₁-C₄ alkoxy or alkylthio, cyano, trifluoromethyl, carboxamido, mono- or di(C₁-C₄ alkyl)carboxamido;

15 m, n and o are independently 0-5, provided that the sum of m, n and o is 2-5;

R² is hydrogen or C₁-C₄ alkyl;

20 R³ and R⁴ combine with the nitrogen atom to which they are attached to form 1-pyrrolidinyl, 1-piperazinyl, 1,2,3,4-tetrahydro-2-isoquinolinyl, 2,3-dihydro-1-indolinyl, 4-morpholinyl, 1-piperidinyl or 1-hexamethyleneiminyl, unsubstituted or substituted with

25 phenyl, naphthyl, (phenyl or naphthyl)(C₁-C₃ alkyl), (phenyl or naphthyl)(C₁-C₃ alkanoyl), amino, mono- or di(C₁-C₄ alkyl)amino, or a group of the formula -NH-Y-R⁵; provided that a piperazinyl or morpholinyl group may not be substituted with amino, mono- or di(C₁-C₄ alkyl)amino, or -NH-Y-R⁵;

30 wherein a phenyl or naphthyl group is unsubstituted or substituted with

-47-

1-3 halo, C₁-C₃ alkyl or C₁-C₃

alkoxy groups;

Y is carbonyl, sulfonyl, aminocarbonyl or oxycarbonyl;

R⁵ is C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₆-C₁₁ bicyclo- or

5 tricycloalkyl, (phenyl or naphthyl)(C₁-C₃ alkyl), phenyl
or naphthyl;

wherein a cycloalkyl, bicyclo- or

tricycloalkyl, phenyl or naphthyl group is

unsubstituted or substituted with 1-3 hydroxy,


10 halo, C₁-C₃ alkyl or C₁-C₃ alkoxy groups;-

or a pharmaceutically acceptable salt thereof.

19. A method of Claim 18 wherein the compound is a
compound wherein m + n + o is 2-4, and R is hydrogen or
alkyl.

15 20. A method of Claim 19 wherein the compound is
N-[2-(4-(1-adamantylcarbonylamino)-1-piperidinyl)ethyl]-1-(2-
propyl)-1H-indazole-3-carboxamide or a pharmaceutically
acceptable salt thereof.

20 21. A method of preparing a compound of the
formula



wherein:

25 R is hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl;

R¹ is hydrogen, halo, C₁-C₄ alkyl, hydroxy, C₁-C₄ alkoxy or
alkylthio, cyano, trifluoromethyl, carboxamido, mono- or
di(C₁-C₄ alkyl)carboxamido;

m, n and o are independently 0-5, provided that the sum of m,

30 n and o is 2-5;


R² is hydrogen or C₁-C₄ alkyl;

-48-

5 R^3 and R^4 combine with the nitrogen atom to which they are attached to form 1-pyrrolidinyl, 1,2,3,4-tetrahydro-2-isoquinolinyl, 2,3-dihydro-1-indolinyl, 1-piperidinyl or 1-hexamethyleneiminyl, substituted with a group of the formula $-NH-Y-R^5$;

 Y is carbonyl;

R^5 is C₃-C₈ cycloalkyl, C₆-C₁₁ bicyclo- or tricycloalkyl, (phenyl or naphthyl)(C₁-C₃ alkyl), phenyl or naphthyl; wherein a cycloalkyl, bicyclo- or
10 tricycloalkyl, phenyl or naphthyl group is substituted with 1-3 hydroxy groups; or a pharmaceutically acceptable salt thereof; comprising reacting a compound of formula I wherein R^3 and R^4
15 combine with the nitrogen atom to which they are attached to form amino-substituted 1-pyrrolidinyl, 1,2,3,4-tetrahydro-2-isoquinolinyl, 2,3-dihydro-1-indolinyl, 1-piperidinyl or 1-hexamethyleneiminyl, with a compound of the formula



20 in the presence of a coupling agent for amide-forming reactions.

 22. A method of Claim 21 wherein the compound of formula I is a compound wherein R^5 is hydroxy-substituted cycloalkyl, bicyclo- or tricycloalkyl.

25 23. A method of Claim 22 wherein the compound of formula I is a compound wherein R^5 is hydroxy-substituted adamantyl.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/03551

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS STRUCTURE, DIALOG, APS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 3,145,215 (KIRCHNER ET AL.) 18 August 1964, see claims 1-12.	1-14, 21-23
A	US, A, 3,678,059 (GSCHWEND ET AL.) 18 July 1972, see column 6 example 1.	1-14, 21-23
A	US, A, 5,387,419 (LEVY ET AL.) 07 February 1995, see entire document.	18-20
A	DE, A, 2,135,398 (MAGDANYI ET AL.) 20 January 1972 see entire document.	1-14, 21-23
A	EP, A, 0,491,664 (SANDOZ LTD.) 24 June 1992, see entire document.	1-14, 21-23
Y	WO, A, 94/00113 (SMITHKLINE BEECHAM PLC.) 06 January 1994, see claims 1-8.	15-20

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A		document defining the general state of the art which is not considered to be of particular relevance
* E		earlier document published on or after the international filing date
* L		document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
* U		document referring to an oral disclosure, use, exhibition or other means
* P		document published prior to the international filing date but later than the priority date claimed
	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
	* A	document member of the same patent family

Date of the actual completion of the international search

30 MAY 1996

Date of mailing of the international search report

12 JUL 1996

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CELIA CHANG

Telephone No. (703) 305-4235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/03551

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO, A, 93/03725 (SMITHKLINE BEECHAM PLC.) 03 April 1993, see entire document and page 12 E10.	1-23
Y	WHITAKER-AZMITIA ET AL. 'The neuropharmacology of serotonin'. New York : The New York Academy of sciences, 1990, vol. 600, pages 195-196 see Tyers, "5HT3 receptorsp" .	15-23
A	Chemical Abstracts, volume 80, No. 7, issued 18 February 1974, Banno et al. "1-Alkyl-3-alkylcarbamoyl-1H-indazoles" see pages 297-298, abstract No. 37103p, Japan Kokai 73-81,858.	1-14
A	Chemical Abstracts, Volume 112, No. 12, issued 19 March 1990, Yagihara et al. "Silver halide photographic materials with good fog inhibition during storage" see page 659, abstract No. 108417m, Japan Koho 01-137,247.	1-10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/03551

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/03551

A. CLASSIFICATION OF SUBJECT MATTER: IPC (6):

A61K 31/415; 31/445; 31/47; 31/495; 31/535
C07D 231/56; 401/12; 403/00; 413/00

A. CLASSIFICATION OF SUBJECT MATTER: US CL :

514/212, 234.5, 255, 307, 322, 403;
540/603;
544/116, 371;
546/148, 199;
548/362.5

B. FIELDS SEARCHED

Minimum documentation searched
Classification System: U.S.

514/212, 234.5, 255, 307, 322, 403;
540/603;
544/116, 371;
546/148, 199;
548/362.5

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claims 1-17, 21-23, drawn to compounds, composition and method of affecting 5HT4 receptors.
Group II, claims 18-20, drawn to method of providing treatment or prophylaxis for anxiety, pain,urinary incontinence, pain of urination.

The inventions listed as Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: at least two independent process of use have been found. The process of affecting receptor is independent of treatment of prophylaxis of anxiety, depression...etc.